Business Context and Reporting Period
This Form 8-K is filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata) on December 3, 2015. The report addresses a regulatory notice regarding the company's stock listing status on The NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock price compliance rather than financial performance metrics.
Material Changes
The material event reported is the failure of the Company's common stock to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, violating NASDAQ Listing Rule 5450(a)(1). This deficiency was identified by the Listing Qualifications Department of The NASDAQ Stock Market LLC.
Outlook, Risks, and Management Commentary
- Cure Period: The Company has been granted a 180-day compliance period ending May 31, 2016, to regain compliance.
- Compliance Path: Compliance can be achieved if the closing bid price remains at or above $1.00 for 10 consecutive business days during the cure period.
- Alternative Option: If compliance is not achieved by May 31, 2016, the Company may apply to transfer to The NASDAQ Capital Market for an additional 180-day period, subject to meeting other listing requirements.
- Risk: Management states there is no assurance that the Company will be able to regain compliance with The NASDAQ Global Market listing requirements.
- Current Status: The notice has no immediate effect on trading; the stock continues to trade under the symbol "SNTA".
Investor Verification Checklist
- Verify the current closing bid price of SNTA stock to assess the likelihood of meeting the 10-day compliance threshold.
- Monitor the Company's progress toward the May 31, 2016, deadline for regaining compliance.
- Review the Company's market value of publicly held shares to determine eligibility for a potential transfer to The NASDAQ Capital Market.
- Check for subsequent filings regarding any reverse stock splits or other corporate actions intended to address the low stock price.